Bibliographic details

Gonzalez-Juanatey JR, Alvarez-Sabin J, Lobos JM, Martinez-Rubio A, Reverter JC, Oyaguez I, Gonzalez-Rojas N, Becerra V.  Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. Revista Espanola de Cardiologia 2012; 65(10): 901-910


This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.

CRD summary

Indexing status

Subject indexing assigned by NLM

Index terms

Aged; Anticoagulants /adverse effects /economics /therapeutic use; Atrial Fibrillation /complications /mortality; Benzimidazoles /adverse effects /economics /therapeutic use; beta-Alanine /adverse effects /analogs & derivatives /economics /therapeutic use; Cost-Benefit Analysis; Embolism /etiology /mortality /prevention & control; Female; Humans; Male; Markov Chains; Spain /epidemiology; Stroke /etiology /mortality /prevention & control; Vitamin K /antagonists & inhibitors; Warfarin /adverse effects /economics /therapeutic use